Autoimmune Diseases
Roche’s Gazyva Shows Promising Results in Phase III Lupus Nephritis Trial
Gazyva, obinutuzumab, lupus nephritis, Phase III REGENCY trial, complete renal response, Roche, autoimmune disease, kidney function
Hinge Bio Secures $30 Million Series A’ Financing for Next-Generation Therapies via GEM-DIMER Platform
Hinge Bio, immune reset, GEM-DIMER platform, Series A’ financing, autoimmune diseases, HB2198, Systemic Lupus Erythematosus
IGM Biosciences Halts Autoimmune Projects Amid Layoffs Following Disappointing Trial Data
IGM Biosciences, layoffs, autoimmune diseases, bispecific antibody T cell engagers, imvotamab, IGM-2644, biotech industry
Candid Therapeutics Expands T-Cell Engager Pipeline with Strategic Collaborations
T-cell engagers, autoimmune diseases, biotechnology, Candid Therapeutics, collaborations, EpimAb Biotherapeutics, Nona Biosciences
Candid Therapeutics Expands T-Cell Engager Portfolio with Three New R&D Collaborations
Candid Therapeutics, T-cell engagers (TCEs), autoimmune diseases, R&D collaborations, biotechnology partnerships
AbbVie Expands Immunology Pipeline with $200M Acquisition of Nimble Therapeutics
AbbVie, Nimble Therapeutics, Immunology, Psoriasis, Autoimmune Diseases, IL23R Inhibitor, Peptide Therapeutics
Q32 Bio Inc. Faces Market Volatility After Bempikibart Program Update
Q32 Bio Inc., bempikibart, autoimmune diseases, IL-7/TSLP pathways, stock performance, market volatility
Nuvig Therapeutics Secures $161M Series B Financing to Advance Immunomodulatory Portfolio
Nuvig Therapeutics, Series B financing, immunomodulatory drugs, autoimmune diseases, chronic inflammatory demyelinating polyneuropathy (CIDP), NVG-2089, clinical trials.
Nuvig Therapeutics Secures $161M Series B Funding for Autoimmune Therapy Development
Nuvig Therapeutics, autoimmune therapy, series B funding, Sanofi Ventures, autoimmune diseases, Fc gamma R2B, immunomodulatory therapy
Nuvig Therapeutics Secures $161M Funding for Phase 2 Study in Autoimmune Diseases
Nuvig Therapeutics, autoimmune diseases, Phase 2 study, funding, NVG-2089, Chronic Idiopathic Demyelinating Polyneuropathy (CIDP), recombinant Fc Ab fragments, synthetic manufacturing.